Feasibility Study of a Home Hospitalisation Strategy for Patients With Heart Failure
NCT ID: NCT04084964
Last Updated: 2022-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2020-10-01
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a Back-to-home Support Program for Hospitalized Patients for Heart Failure
NCT05566145
Predicted Prognosis in Heart Failure
NCT04009798
Heart Failure Patient Self-Management Web Portal Pilot Study
NCT01009151
Readmission Risk of Patients With Heart Failure.
NCT04984928
Effectiveness of a Website and Telemonitoring in Patients With Heart Failure.
NCT01755988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are treated by a team of specialised nurses under supervision of a cardiologist. The nurses visit patients at least once a day and are equipped with laboratory equipment and IV medication administering equipment. These devices and equipment are currently used in standard HF care and are not part of the newly developed home hospitalisation platform. Patients receive treatment similar to in-hospital treatment, according to the cardiologist's best knowledge and insight.
In the case of Jessa Hospital, if there would be a need for IV medication during the home-hospitalisation period, this will lead to rehospitalisation of the patient and the ending of the intervention. In Isala, the nurses have a 24/7 duty service and can be called by patients or their relatives on their own initiative. In Jessa hospital and MUMC+, the nursing team can be contacted between 9 AM and 17 PM. During other hours, the patients can contact the cardiologist on call.
In case of treatment failure or severe deterioration, patients will be transported to the hospital. In case of emergency, ambulances will transport patients to the hospital (conversion to regular hospitalisation). If in follow-up, condition worsens, the patient can be readmitted at home again. In theory, patients may undergo repeated hospitalisations at home.
The home-hospitalisation period will last at least 5 days and can be extended, till a maximum of 13 days, after consultation of a cardiologist. Patient will be asked to fill in questionnaires to assess feasibility at the end of the home-hospitalisation period (last visit of nurse). At the last visit of the nurse, she will take all the devices with her.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
These patients receive the home-hospitalisation platform
Home-hospitalisation platform for heart failure
The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Home-hospitalisation platform for heart failure
The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age\>18 years
* (Indication for) hospital admission for acute decompensated heart failure
* Living within a wide proximity of the hospital (differs per centre)
* Living independently and/or sufficiently supported at home and/or living in nursing homes (or other supported living modalities).
Exclusion Criteria
* Contraindication to Chance@Home;
* Mental impairment leading to inability to cooperate;
* Severe comorbidity requiring simultaneous hospital care;
* History of severe liver / kidney disease;
* Unstable blood pressure (systolic blood pressure \<90mmHg);
* Unstable heart rhythm (in case of sinus rhythm, heart rate \>110/min, in case of atrial fibrillation \>150/min);
* Need for intravenous inotropic medication;
* Unstable respiratory condition (sO2 \<90% without additional O2)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Isala
OTHER
Maastricht University Medical Center
OTHER
Hasselt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
prof. dr. Paul Dendale
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jessa Hospital
Hasselt, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Leenen JPL, Scherrenberg M, Bruins W, Boyne J, Vranken J, Brunner la Rocca HP, Dendale P, van der Velde AE. Usability of a digital health platform to support home hospitalization in heart failure patients: a multicentre feasibility study among healthcare professionals. Eur J Cardiovasc Nurs. 2024 Mar 12;23(2):188-196. doi: 10.1093/eurjcn/zvad059.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NWE 661
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.